Aligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLD’s The Liver Meeting® 2022
Aligos Therapeutics, Inc. (Nasdaq: ALGS) presents promising data from its Phase 1 study of ALG-000184, a small molecule capsid assembly modulator for chronic hepatitis B (CHB). Key results include reductions in hepatitis B surface antigen levels in subsets of subjects, with three out of seven receiving 300 mg showing reductions of 0.2-0.8 log10 IU/mL. Additionally, all subjects exhibited significant declines in HBV DNA (mean decline of 4.2 log10 IU/mL) and RNA levels (mean decline of 3.1 log10 copies/mL). These findings suggest ALG-000184 might have superior antiviral properties, warranting further study.
- 3 out of 7 subjects on 300 mg ALG-000184 showed HBsAg reductions of 0.2-0.8 log10 IU/mL.
- All subjects experienced significant declines in HBV DNA and RNA, with mean declines of 4.2 log10 IU/mL and 3.1 log10 copies/mL, respectively.
- Initial data indicates ALG-000184 may possess best-in-class antiviral properties.
- Additional cohorts have been initiated to confirm these encouraging results.
- The dataset is small and preliminary, requiring further validation.
- There is uncertainty over whether HBsAg reductions will continue with longer treatment durations.
Reductions in hepatitis B surface antigen levels observed in a subset of subjects with chronic hepatitis B enrolled in Phase 1 study ALG-000184-201
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, will deliver a poster presentation at The Liver Meeting® (November 4-8, 2022), hosted by the American Association for the Study of Liver Diseases (AASLD). The poster highlights clinical data for its small molecule capsid assembly modulator-empty capsid (CAM-E) drug candidate, ALG-000184, which is in development for the treatment of chronic hepatitis B (CHB). The poster includes the following key results from the ongoing Phase 1 study ALG-000184-201 (NCT04536337) in HBeAg-positive CHB cohorts that received 28 daily oral doses of ALG-000184 at either the 100 mg or 300 mg dose levels:
- ALG-000184 reduced hepatitis B surface antigen (HBsAg) levels in a subset of HBeAg-positive subjects
- Among 7 subjects with evaluable HBsAg data who were treated with 300 mg ALG-000184, 3 subjects experienced reductions in HBsAg levels of 0.2-0.8 log10 IU/mL
- One subject in the 100 mg ALG-000184 cohort experienced a reduction in HBsAg levels of 0.5 log10 IU/mL
- Rapid and profound reductions in hepatitis B virus (HBV) DNA and RNA were observed in all subjects
- HBV DNA mean decline: 4.2 (100 mg), 4.0 log10 IU/mL (300 mg)
- HBV RNA mean decline: 3.1 (100 mg), 2.6 log10 copies/mL (300 mg)
“We are excited about these preliminary data on the most advanced candidate in Aligos’ CHB portfolio,” said Lawrence Blatt, Ph.D., MBA, CEO and Chairman of the Board at Aligos. “While this dataset is small and needs to be confirmed, the observed reductions in viral surface antigen over such a short duration with an oral treatment have not been seen before. Combined with the potent reductions in HBV DNA and RNA, these new data indicate that ALG-000184 may have best-in-class antiviral properties. Based on these data, we have initiated additional cohorts in this study to confirm these observations and explore the impact of treatment for up to 48 weeks on HBsAg levels.”
“The HBsAg-lowering effects of ALG-000184 over this short dosing period are unprecedented for CAMs and therefore very exciting,” said Ed Gane, Professor of Medicine at the University of Auckland and an Investigator in the study. “If this decline in HBsAg levels continues during longer durations of therapy, then oral CAM-E drugs could become an important component of a combination regimen that can achieve functional cure.“
Aligos’ poster presentations at The Liver Meeting collectively highlight new data from the company’s drug candidates targeting chronic hepatitis B (CHB) and nonalcoholic steatohepatitis (NASH) and are available on the Aligos website at Scientific Presentations & Conferences.
Poster details
Title: Safety, pharmacokinetics (PK), and antiviral activity of the capsid assembly modulator (CAM) ALG-000184 in subjects with HBeAg positive chronic hepatitis B (CHB)
Poster Number: 1329
Abstract Number: 33693
Presenter: Jinlin Hou, M.D., Nanfang Hospital of Southern Medical University
About Aligos
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including, without limitation, statements that the new data indicate that ALG-000184 may have best-in-class antiviral properties and if the decline in HBsAg levels continues during longer durations of therapy, that oral CAM-E drugs could become an important component of a combination regimen that can achieve functional cure. Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Aligos’s clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos’s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos’s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic and the ongoing conflict between Russia and Ukraine. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 2, 2022 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Media Contact
Amy Jobe, Ph.D.
LifeSci Communications
+1 315 879 8192
ajobe@lifescicomms.com
Investor Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
FAQ
What results were presented for ALG-000184 at The Liver Meeting?
What is the significance of the HBsAg reductions observed in the study of ALG-000184?
What is the next step for Aligos after the Phase 1 study results of ALG-000184?
What are the dosing levels evaluated in the ALG-000184 trial?
How many subjects experienced significant reductions in HBsAg levels in the study?
